Abstract
In an interview with Health Affairs founding editor John Iglehart, Ron Dollens outlines the differences between drug and device companies in the current U.S. health care marketplace. He discusses at length the recent Medicare coverage decision regarding implantable cardiac defibrillators, one of his company's major innovations. He sees a growing trend for cost-effectiveness to be considered along with a device's safety and efficacy, and he finds this to be appropriate in an environment characterized by constrained resources. He believes that the United States must find a solution to the problem of uninsurance, if our health care system is to remain competitive in a global economy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
